Autolus Therapeutics

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Autolus reports robust Q4 performance, poised for CAR T therapy success

Autolus Therapeutics demonstrated strong operational and financial performance in Q4 2022, supported by key partnerships and successful clinical data for obe-cel.
While facing challenges in competitive positioning and pricing strategy, the company has opportunities to capitalize on upcoming milestones and data releases to drive growth.
By focusing on long-term data integrity and strategic market positioning, Autolus aims to establish obe-cel as a leading therapy in the CAR T landscape.

Autolus Therapeutics reports Q1 loss, highlights CAR T progress

Autolus Therapeutics showcased progress with CAR T programs and a strong financial position
The company's focus on Obe-cel and collaborations with key partners present growth opportunities
Challenges include data disclosure queries, program potential, and partnership considerations
Opportunities lie in extending runway, expanding collaborations, and exploring new indications

Autolus Therapeutics reports strong Q2 results and eyes market expansion

Autolus Therapeutics is on track with its lead program, Obe-cel, and is making strategic moves to enhance its product portfolio and operational capabilities.
The company's financial performance remains stable, with a focus on cost management and extending its cash runway into 2025 through milestone payments.
Despite facing challenges in expense management and regulatory processes, Autolus is well-positioned to capitalize on opportunities in new indications and product development.

Autolus Therapeutics reports strong Q3 earnings and pipeline advancements

Autolus Therapeutics is making significant progress with its pipeline programs, focusing on advancing obe-cel for autoimmune diseases and presenting data at ASH.
The company's strong financial position and anticipated milestones, such as BLA filing and AUTO8 program updates, provide a solid foundation for future growth.
While facing challenges in a competitive market and logistical hurdles for pivotal trials, Autolus has opportunities to differentiate its offerings and strengthen its position in new indications.

Autolus Therapeutics reports strong financials and strategic growth opportunities

Autolus Therapeutics had a successful year financially and operationally, well positioned with a cash reserve for upcoming milestones and program expansions.
While facing regulatory challenges and cost management considerations, the company is strategically focused on expanding its therapeutic opportunities and enhancing operational efficiency.
Opportunities lie in exploring new indications, streamlining patient enrollment processes, and leveraging partnerships for broader market access and growth.

Autolus reports robust Q1 earnings, poised for strategic growth

Autolus Therapeutics demonstrated strong financial performance with increased revenue and cash reserves, positioning the company well for upcoming milestones and commercialization efforts.
While facing challenges related to accounting matters and escalating operating expenses, Autolus remains well-prepared for the launch of obe-cel and future pipeline developments.
Opportunities lie in upcoming regulatory reviews, milestone conferences, and potential treatment regimen evolution in the autoimmune space, signaling a promising outlook for Autolus.

Autolus reports robust Q3 earnings, poised for growth and innovation

Autolus Therapeutics demonstrated strong financial performance and progress in its CAR T therapy programs in Q3 2024, supported by milestone payments and a robust manufacturing facility.
While well-capitalized and positively received by physicians, the company faces challenges in cost guidance, market access strategies, and pediatric trial outcomes.
Opportunities lie in upcoming milestones, pediatric market positioning, and operational efficiency improvements, positioning Autolus for continued growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

- Obe-cel shows sustained durability of response with morphological EFS of 46% at 24 months in the ALLCAR19 study

Autolus Therapeutics presents positive obe-cel data at the 63rd ASH Annual Meeting & Exposition

Conference Call and Webcast to be held on Monday, December 13, 2021 at 8:00 am ET / 1:00 pm GMT Conference Call and Webcast to be held on Monday, December 13, 2021 at 8:00 am ET / 1:00 pm GMT

Autolus Therapeutics announce new time for investor call to discuss data presented at the 63rd ASH Annual Meeting & Exposition

LONDON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. William D. Young, a Senior Advisor to Blackstone Life Sciences, has been appointed as a non-executive director to its board of directors, effective immediately. The appointment is pursuant to the recently announced investment from Blackstone Life Sciences. Dr. Young will serve as a Class III director, with an initial term expiring at Autolus' 2024 annual general meeting. Dr. Young brings to Autolus more than 50 years of experience in the life science industry, most notably prior service as Chief Operating Officer of Genentech and Chairman of the Board of Biogen.

Autolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director

Tetracycline and minocycline controllable CAR T cell system to manage toxicities Tetracycline and minocycline controllable CAR T cell system to manage toxicities

Autolus Therapeutics announces publication describing its small molecule-regulated CAR T cells

Blackstone Group

Tesla

Roblox Corp (NYSE: RBLX) shares jumped 30% after hours on Monday after the company posted robust fiscal Q3 results thanks to demand surge with the easing of COVID-19 restrictions. As a result, the video game company reported a loss of $74 million or $0.13 per share compared to a net loss of $48.6 million or […] The post Market Highlights: Stocks react to earnings release, Blackstone invests $250 billion in Autolus, Elon Musk to sell 10% Tesla stake appeared first on Invezz.

Market Highlights: Stocks react to earnings release, Blackstone invests $250 billion in Autolus, Elon Musk to sell 10% Tesla stake

A private equity firm is taking a $100 million stake in the biotech.

Why Autolus Therapeutics Stock Jumped 25% Today

Autolus Therapeutics (AUTL) stock is surging higher in trading Monday following news of a major investment in the company. The post AUTL Stock: Why Little-Known Autolus Therapeutics Is Rocketing Higher Today appeared first on InvestorPlace.

AUTL Stock: Why Little-Known Autolus Therapeutics Is Rocketing Higher Today

Shares of Autolus Therapeutics plc (NASDAQ: AUTL) jumped about 30% in premarket trading on Monday after it said Blackstone Life Sciences agreed to invest up to $250 million to fund the development of its new therapy for Leukemia. Blackstone is taking a sizable equity stake in Autolus Blackstone is taking an equity stake worth $100 […] The post Blackstone triggers a 30% increase in Autolus Therapeutics shares appeared first on Invezz.

Blackstone triggers a 30% increase in Autolus Therapeutics shares

The stock price of Autolus Therapeutics PLC (NASDAQ: AUTL) increased by over 25% pre-market today. This is why it happened.

Autolus Therapeutics (AUTL) Stock: Why The Price Surged Today

– One of the largest private financings of a UK biotech company, and the largest from a single source – continues Blackstone conviction in the country

Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform

Blackstone Inc. is investing as much as $250 million in U.K. biotechnology company Autolus Therapeutics PLC to fund the final stages of development of a new therapy to treat a serious form of leukemia, the companies said.

The Wall Street Journal: Blackstone to invest up to $250 million in British biotech company Autolus

- Demonstrates progress on the Company's commercial manufacturing process and builds on positive obe-cel clinical data presented at EHA

Autolus Therapeutics to Present New Data at the 63rd ASH Annual Meeting & Exposition

Autolus Therapeutics plc (AUTL) CEO Dr. Christian Itin on Q3 2021 Results - Earnings Call Transcript

Conference call to be held on November 3, 2021, at 8:30 am ET/12:30 pm GMT Conference call to be held on November 3, 2021, at 8:30 am ET/12:30 pm GMT

Autolus Therapeutics Reports Third Quarter 2021 Financial Results and Operational Progress

LONDON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2021 financial results and operational highlights before open of U.S. markets on Wednesday, November 3, 2021.

Autolus Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3

- Allowing global commercial launch capacity for obe-cel (AUTO1) - Allowing global commercial launch capacity for obe-cel (AUTO1)

Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK

LONDON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that John H. Johnson has been appointed as non-executive chairman of its Board of Directors, effective September 15, 2021. Dr. Martin Murphy, who previously served as chairman, will continue to serve as a non-executive Board member.

Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors

BASEL, Switzerland--(BUSINESS WIRE)--Novaremed AG, a privately held clinical-stage biopharmaceutical company, announces the acquisition of Metys Pharmaceuticals AG (Metys), including all of its development programs, in an all-share transaction. The acquisition broadens Novaremed's existing pipeline by adding both clinical and preclinical development projects based on an innovative approach for non-opioid chronic pain treatment, the Company's focus area. Moreover, it enables Novaremed to target

Novaremed Expands its Pipeline of Non-opioid Treatment Candidates for Chronic Pain Indications Through Acquisition of Metys Pharmaceuticals

The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted Promising Innovative Medicine (PIM) designation to Autolus Therapeutics plc's (NASDAQ: AUTL) AUTO1 (obecabtagene autoleucel, obe-cel). The Company's CAR T cell therapy is being investigated in the ongoing FELIX Phase 1b/2 study in relapsed/refractory adult B-cell Acute Lymphocytic Leukemia (ALL) in patients 18 years and older.

Autolus' Blood Cancer CAR T-Cell Therapy Receives Promising Innovative Medicine In UK

Autolus Therapeutics plc (AUTL) CEO Christian Itin on Q2 2021 Results - Earnings Call Transcript

Potential licensing agreements with Moderna are giving investors reasons to cheer.

Here's Why Autolus Therapeutics Is Surging Today

The stock price of Autolus Therapeutics PLC (NASDAQ: AUTL) increased by over 15% pre-market. This is why it happened.

AUTL Stock Increases Over 15% Pre-Market: Why It Happened

LONDON, July 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Edgar Braendle M.D., Ph.D., as chief development officer. Dr Braendle is joining Autolus' executive team today and will lead the company's development organization.

Autolus Announces Appointment of Edgar Braendle, M.D., Ph.D., as Chief Development Officer

LONDON, July 08, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2021 financial results and operational highlights before open of U.S. markets on Thursday, August 5, 2021.

Autolus Therapeutics to Report Second Quarter 2021 Financial Results on August 5, 2021, and will Participate in the William Blair Biotech Focus Conference 2021 on July 14, 2021

LONDON, June 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has received innovative licensing and access pathway (ILAP) designation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for AUTO1 (obecabtagene autoleucel, obe-cel), the company's CAR T cell therapy being investigated in the ongoing FELIX Phase 1b/2 study in relapsed / refractory (r/r) adult B-cell Acute Lymphocytic Leukemia (ALL) in patients 18 years and older.

Autolus Therapeutics Announces Innovation Licensing and Access Pathway (ILAP) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL

News for Autolus Therapeutics Stock (AUTL)